Ho DH - Search Results

1

Ho DH, Covington WP, Legha SS, Newman RA, Krakoff IH. Ho DH, et al. Clin Pharmacol Ther. 1987 Sep;42(3):351-6. doi: 10.1038/clpt.1987.160. Clin Pharmacol Ther. 1987. PMID: 2957140

2

Clinical pharmacology of polyethylene glycol-L-asparaginase.

Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A, Newman RA, Krakoff IH. Ho DH, et al. Drug Metab Dispos. 1986 May-Jun;14(3):349-52. Drug Metab Dispos. 1986. PMID: 2872037

3

Clinical pharmacology of 11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo (7.4.1.0(2,7).0(10,12) tetradeca-2,4,6-trien-6,9-diyl diacetate (FK 973).

Ho DH, Pazdur R, Brown NS, Covington WP, Raber MN, Krakoff IH. Ho DH, et al. Anticancer Res. 1993 Mar-Apr;13(2):343-6. Anticancer Res. 1993. PMID: 8517646

4

Clinical pharmacology of combined oral uracil and ftorafur.

Ho DH, Covington WP, Pazdur R, Brown NS, Kuritani J, Newman RA, Raber MN, Krakoff IH. Ho DH, et al. Drug Metab Dispos. 1992 Nov-Dec;20(6):936-40. Drug Metab Dispos. 1992. PMID: 1362949 Clinical Trial.

5

Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion.

Ho DH, Brown N, Lin JR, Covington W, Newman RA, Raber M, Amato R, Schmidt S, Krakoff IH. Ho DH, et al. Drug Metab Dispos. 1991 May-Jun;19(3):643-7. Drug Metab Dispos. 1991. PMID: 1717216

6

Effects of cisplatin-induced nephrotoxicity on gentamicin pharmacokinetics in rats.

Engineer MS, Bodey GP Sr, Newman RA, Ho DH. Engineer MS, et al. Among authors: ho dh. Drug Metab Dispos. 1987 May-Jun;15(3):329-34. Drug Metab Dispos. 1987. PMID: 2886307

7

Phase I trial of a 72-h continuous-infusion schedule of fazarabine.

Amato R, Ho D, Schmidt S, Krakoff IH, Raber M. Amato R, et al. Cancer Chemother Pharmacol. 1992;30(4):321-4. doi: 10.1007/BF00686303. Cancer Chemother Pharmacol. 1992. PMID: 1379523 Clinical Trial.

8

Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits.

Ho DH, Wang CY, Lin JR, Brown N, Newman RA, Krakoff IH. Ho DH, et al. Drug Metab Dispos. 1988 Jan-Feb;16(1):27-9. Drug Metab Dispos. 1988. PMID: 2894951

9

Phase I trial of FK973: description of a delayed vascular leak syndrome.

Pazdur R, Ho DH, Daugherty K, Bradner WT, Krakoff IH, Raber MN. Pazdur R, et al. Among authors: ho dh. Invest New Drugs. 1991 Nov;9(4):377-82. doi: 10.1007/BF00183587. Invest New Drugs. 1991. PMID: 1804817 Clinical Trial.

10

Metabolism and disposition of (R)-4-[3-(2-hydroxy-2-phenyl)ethylamino-3-methylbutyl]benzamide Hcl (LY 195448) in rodents.

Ho DH, Covington WP, Lin J, Brown NS, Newman RA. Ho DH, et al. Res Commun Chem Pathol Pharmacol. 1989 Nov;66(2):255-67. Res Commun Chem Pathol Pharmacol. 1989. PMID: 2602657

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209 results

Search Page

Filters